Target intelligence / Profile preview

BCL2 interacting protein 3 pseudogene 30 (BNIP3P30)

Target
BNIP3P30
Molecular classification
Other (Pseudogene)
01

Overview

BCL2 interacting protein 3 pseudogene 30 (BNIP3P30) is classified as a noncoding pseudogene, meaning it is a DNA sequence similar to the protein-coding gene BNIP3 but does not encode a functional protein[1][5]. Pseudogenes may, in some cases, have regulatory functions at the RNA level, such as acting as competing endogenous RNAs (ceRNAs) or regulating their parent gene's expression. However, there is no evidence that BNIP3P30 has a validated role in any molecular pathway, disease process, or as a drug target. Any functional roles described in the literature relate to other BNIP3 pseudogenes or the functional BNIP3 gene, not BNIP3P30 specifically[1][2][5]. Therefore, BNIP3P30 is not considered a therapeutic target and its mention as a receptor or enzyme is incorrect.

Other names
BCL2/adenovirus E1B 19kDa interacting protein 3 pseudogene 30BNIP3P30
02

Mechanism of action

None

03

Biological functions

None directly assigned; as a pseudogene, BNIP3P30 does not produce a functional protein.It may play regulatory roles as a noncoding RNA in gene regulation, based on pseudogene-related literature[1][2][8].
04

Disease associations

Other (no direct evidence implicating BNIP3P30 in specific diseases; however, related pseudogenes sometimes participate in gene regulation. The functional BNIP3 gene is involved in apoptosis and cancer, but this does not extend to BNIP3P30)[1][2].
05

Safety considerations

None
06

Interacting drugs

None (no drugs target this pseudogene)
07

Biomarkers

None

Beyond the preview

Go deeper on BCL2 interacting protein 3 pseudogene 30 (BNIP3P30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 30 (BNIP3P30).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call